

WHITE PAPER

# INNOVATION IN MOTION

Harnessing Digital Technology to Predict, Optimize,  
and Secure the Pharma Logistics Supply Chain





# Table of Contents

<b>1. Introduction</b>	1
Background	
<b>2. Challenges in Pharmaceutical Logistics</b>	1
Cold Chain Management and Product Stability	
Product Diversity	2
Regulatory Compliance	
Supply Chain Visibility	3
Real-time Visibility and Technology Limitations	
Data Availability and Standardization	
Environmental Sustainability	4
CO2 Emissions	
Waste Management	
<b>3. Pharmaceutical Logistics Trends &amp; Requirements</b>	5
Predictive & Prescriptive Analytics and Behaviour Modelling	
Standardization and Data Collaboration	6
End-to-End Visibility and Real-time Tracking	7
Optimization of Logistics Operations, Costs and Sustainability	8
Innovations in Medical Treatments	9
Decentralized clinical trials	
Cell & Gene Therapy	
Radioactive Medicine at Nano Level	
<b>4. Digital Solutions for Evolving Trends and Challenges</b>	10
Achieving End-to-End visibility in Cold Chain with Internet of Things (IoT) and Sensors	
Enabling Predictive Risk Mitigation with Artificial Intelligence (AI)	11
Provide Transparency and Security with Blockchain Technology	
Combined Digital Solutions for Sustainability Improvement	12
<b>5. Case Study: MSD – Applicability of Next-Gen Digital Technologies</b>	13
<b>6. Implementation Challenges and Enablers for Digital Solutions</b>	15
Infrastructure and Integration	
Data Security and Privacy	16
Regulatory Compliance	
Training and Workforce Skills	
Rapid Innovations	17
Precision & Personalized Medicine	
<b>7. Exploring Emerging Trends and Transformations</b>	18
Sectoral Changes Impacting Life Sciences and Pharma in the Next Years	
Converging Technologies: Self-driving Supply Chain	19
<b>8. Conclusions</b>	20



## Introduction

### Background

In recent years, there has been an exponential growth in the adoption of next-generation digital technologies, particularly within the healthcare and clinical trials domains. These technologies have demonstrated the potential to revolutionize various aspects of research and development, including clinical trials and interventions.

Recognizing the imminent need for a shift in the air cargo industry and the end-to-end supply chain, Pharma.Aero embarked on a researching project. The primary objective is to gain comprehensive insights into the practical application of next-generation digital technologies throughout the life science and MedTech logistics ecosystem. By doing so, Pharma.Aero aims to provide a holistic understanding of these technologies, their technical prerequisites, and their alignment with the evolving healthcare landscape.

### Project Team

**Samuel Speltdoorn**

| Brussels Airport Company | Pharma.Aero Board Liaison

**Yue Ming, Liew Zhong Yao, Renee Gan**

| Changi Airport Group | Project Lead

**Irene S L Lau, Caroline Y W Cheung, Sharon S K Yip**

| Hong Kong Airport Authority | Project Lead

**Virginia Domina, Righart Stroobant,  
Anne Julie Verhaeghe**

| KPMG | Project Expert, Project Manager

**Sara Van Lerberghe**

| Pharma.Aero Project Coordinator

**Frank Van Gelder**

| Pharma.Aero Secretary General

## Challenges in Pharmaceutical Logistics

*In the intricate network of the pharmaceutical supply chain, the process of delivering life-saving medications from manufacturers to the end-users is a journey of paramount importance and its seamless execution is a complex orchestration with numerous challenges.*

### Cold Chain Management and Product Stability


The safety and efficacy of many pharmaceutical products, particularly drugs, vaccines and biologics, are highly impacted by a multitude of fluctuating environmental factors during transport, such as temperature, humidity levels, light exposure, shock, pressure changes, and acceleration forces. Proper control during transportation is critical for patient safety. Cold chain management and product stability are being challenged by multiple aspects such as the very sensitive nature of products, cold chain infrastructure, packaging, increasing product diversity and the development of new concepts such as cell therapy requiring personalized supply chains.



## Product Diversity

Pharmaceutical logistics involves a wide range of products with varying requirements and the industry is constantly evolving with new products, therapies, and temperature-sensitive treatments. This dynamic nature demands that the supply chain infrastructure remains adaptable to evolving temperature and environment requirements.

A prime example is the supply chain for CAR-T therapy. A patient's own white blood cells are collected, transported, engineered at a lab, and returned for administration. This patient-specific approach demands a highly specialized and adaptable logistics network to meet the unique requirements of each case.



## Regulatory Compliance

The pharmaceutical industry operates within a highly regulated environment, guided by an intricate web of guidelines and standards designed to ensure the integrity, safety, security and efficacy of pharmaceutical products. Among these regulations, Good Distribution Practices (GDPs) and Good Manufacturing Practices (GMPs) stand out, setting stringent requirements for the transportation and storage of pharmaceutical goods.

Non-compliance with regulations carries significant consequences, including financial penalties, legal ramifications, and reputational damage. According to APQC research<sup>1</sup>, 75% of companies involved in the pharmaceutical supply chain identify regulations as the most significant obstacle to improving supply chain processes.

The rigorous regulatory standards (e.g., GMD, GDP) together with the industry's risk-averse culture, have fostered a cautious approach to adopting new technologies and innovations in the sector. Given the potentially negative consequences of even minor errors in drug development, manufacturing, or distribution, stakeholders across the supply chain approach new solutions with utmost caution, contributing to the slow adoption of new technologies.

<sup>1</sup> 2022 Process and Performance Management Priorities and Challenges: Manufacturing Sector | APQC



## Supply Chain Visibility

### Real-time Visibility and Technology Limitations

Real-time visibility requires continuous information flow that grants the ability to track the trajectory and precise status of goods at any moment.

The existing adopted technological landscape sometimes falls short of providing robust solutions to achieve real-time supply chain visibility, intensifying the challenges inherent in pharmaceutical logistics.

Even with real-time data capabilities, there can be challenges in ensuring that technology is widely implemented and integrated into the supply chain processes. Furthermore, network infrastructure plays a crucial role in enabling the seamless transmission of this real-time data. These factors, among others, can influence the ability to provide immediate, context-rich data, which is essential for proactive responses to emerging challenges

“Acceptance of new technology is increasing, but it is still moving slowly.”

~ Mytigate

## Data Availability and Standardization

Pharmaceutical supply chains fare complex global networks with diverse entities, each operating with unique IT systems. This results in fragmented data streams from sources like RFID tags, GPS sensors, and IoT devices, posing significant challenges in managing and validating the information:

**Fragmentation of Data Sources**

**Legacy Systems**

**Data Heterogeneity**

**Connectivity Limitations**

**Reluctance in Data Sharing**

**Data Privacy and Security Challenges**



## Environmental Sustainability

### CO2 Emissions

The healthcare industry, committed to well-being, is a major contributor to the climate crisis, and this comes from factors like energy consumption, transportation, and the product lifecycle, spanning from manufacturing to disposal.

While manufacturing carries a large carbon footprint, the distribution of medicines (particularly temperature-sensitive), from the factory and into patients' hands also has a significant impact on the environment.

### Scope 3 Emissions Tracking & Reporting

Tracking and reporting Scope 3 emissions is critical for companies to fully understand their carbon footprint and develop effective sustainability strategies, in line with the latest Climate Change regulations. However, there are several challenges that companies face when tracking and reporting Scope 3 emissions.

**Data Collection  
Challenge**

**Complexity of  
Measurement**

**Data Validation**

### Waste management

Waste generation and waste management is a crucial concern in many sectors. To tackle the increasing amounts of packaging waste that are causing environmental problems, the EU implements the PPWR (Packaging and Packaging Waste Regulation) with clear regulations on packaging and packaging waste, including design and waste management in a circular economy principle. It is the 5R principles Remove – Reduce – Reuse – Recycle – Repurpose.<sup>2</sup>

The pharmaceutical industry is not excluded from facing challenges in effectively managing waste within its logistics operations. Two prominent aspects contributing to waste generation are packaging materials and temperature control & product stability failures. These challenges lead not only to significant financial losses but, additionally, to environmental concerns. Temperature failures result in wasted products, clinical trial losses, replacement costs, and the expenses associated with root-cause analysis. In temperature-controlled pharmaceuticals, waste exceeded 15%. Around 25% of vaccines are degraded due to incorrect shipping, 30% of scrapped pharmaceuticals stem from logistics issues, and 20% of temperature-sensitive products are damaged in transit due to cold chain disruptions,<sup>3</sup> resulting in a loss of over \$35 billion per year.<sup>4</sup>

<sup>2</sup> Packaging waste (europa.eu)

<sup>3</sup> Discovering the Importance of Cold Chain Logistics – All Things Supply Chain

<sup>4</sup> IQVIA Institute for Human Data Science.



## Pharmaceutical Logistics Trends & Requirements

Fortunately, given the challenges, the constant evolution of the pharmaceutical industry, the shifting supply chain dynamics, and the ever-changing business landscape, the pharmaceutical sector is actively embracing and adapting to new trends.

### Predictive & Prescriptive Analytics and Behaviour Modelling

Companies involved in the pharma supply chain are adopting predictive analytics and behaviour modelling concepts to anticipate potential disruptions, optimize routing, and improve decision-making based on historical data, real-time inputs, and algorithms. These techniques leverage data and advanced analytics to make informed predictions about various aspects of the supply chain, helping pharmaceutical companies and logistics providers make better decisions.

Within analytics, different levels of insight and foresight gathering are distinguished:

In the pharmaceutical logistics sector, predictive analytics can play a crucial role, for example, in anticipating temperature excursions. Prescriptive analytics can take the predictive insights a step further by recommending specific actions to address potential temperature stability issues, such as adjustments to packaging materials, insulation, and even different route selection. This proactive approach allows the company to not only prevent temperature excursions but also optimize its processes for maximum product stability while minimizing the potential waste or damage.

<b>Descriptive analytics:</b>	"What has happened?"
<b>Diagnostic analytics:</b>	"Why did it happen?"
<b>Predictive analytics:</b>	"What will happen?"
<b>Prescriptive analytics:</b>	"How can I make it (not) happen?"



## Standardization and Data Collaboration

Data sharing and standardization are crucial to enhance efficiency, transparency, and collaboration across the supply chain.

### Data standardization

involves establishing uniform data formats, protocols, and communication standards that all stakeholders adhere to. This ensures that data can be easily exchanged and interpreted across different systems and platforms. Standardization fosters interoperability among diverse technology systems and software platforms to enable seamless data sharing and integration.

“Data collection is a big challenge, the format of the data and the decentralised nature: multiple reports, databases, dashboards, pdfs files and Excel tables.”

~ Lainpharma

### Data collaboration

entails creating a collaborative ecosystem where various stakeholders (manufacturers, distributors, carriers, customs authorities, regulatory bodies) can securely share relevant information to facilitate streamlined communication, reduce delays, and ensure access to precise and timely data.

Achieving data standardization and collaboration requires a concerted effort from all stakeholders in the pharmaceutical supply chain.

“In a data-sharing community, companies can benefit from both the availability and quality of the shared information.”

~ Mytigate

One notable initiative in this regard is the IATA One Record data exchange standard. The vision for ONE Record is to establish an end-to-end digital logistics and transport supply chain where data is easily and transparently exchanged in a digital ecosystem of air cargo stakeholders, communities and data platforms.

Overall, data standardization and data collaboration are essential trends that enable pharmaceutical companies to streamline operations, enhance quality control, and ensure the safe and efficient transportation of critical medical products.





## End-to-End Visibility and Real-time Tracking

End-to-end visibility and real-time tracking in pharmaceutical logistics refer to the comprehensive oversight and continuous monitoring of the entire journey of pharmaceutical products.

End-to-end visibility and real-time tracking bridges the gaps between multiple stakeholders, diverse transportation modes, and variable environmental conditions, responding to this major concern. The current development of end-to-end visibility and real-time tracking is a direct response to the complexities that arise from the challenges faced by the industry.


“ Visibility and reliability: the combination of the two is needed.”

~ Air Logistics Group

“ Every company is different and has a different need, but they can build an overview of advantages of having E2E visibility, instead of shipment visibility.”

~ Zoetis

Achieving end-to-end visibility and real-time tracking brings direct benefits, for example it facilitates real-time response to temperature and environmental factor changes. Additionally, quality assurance teams are offered comprehensive risk management tools with timely information.





## Optimization of Logistics Operations, Costs and Sustainability

The optimization of logistics operations, costs, and sustainability is a direct response to the multifaceted challenges faced by the pharmaceutical industry in its goal of ensuring efficient, cost-effective, and environmentally responsible transportation of pharmaceutical products.

The rising costs of transportation, energy, and resources, coupled with the global focus on sustainability and environmental impact, have created a pressing need for innovative solutions that address these challenges while enhancing overall logistics performance.

By implementing new technologies and digital solutions, companies aim to achieve seamless, sustainable and cost-effective supply chain operations.

“ Optimization solutions are more and more needed to decrease costs and work on sustainability: route optimization, packaging optimization...”

~ Validaide

## Pharmaceutical Industry's Drive Towards Sustainability

In recent years, the pharmaceutical industry has emerged as a key player in addressing the urgent need for sustainability and leveraging digital transformation to create a more efficient and environmentally responsible supply chain.

A great use case example is the development of packaging materials through behaviour modelling by utilizing advanced technologies to design packaging that is not only efficient but also tailored to specific usage scenarios. It involves creating digital simulations and models to predict how packaging will perform under various conditions and stressors throughout its lifecycle.

Optimized packaging design leads to cost savings in multiple ways. By eliminating over-engineering and excess material usage, companies can reduce material costs. Moreover, packaging that effectively protects products will prevent damage and the associated costs of product replacement.

The pharmaceutical industry's growing ambition is evident through an increase in initiatives aimed at mitigating its environmental impact in recent years. An explanatory example of this is the establishment of the Health Systems Taskforce (HST) during the 26th United Nations Climate Change Conference (COP26) in 2021.



## Innovations in Medical Treatments

In recent years, there has been a rapid acceleration of innovations in medical treatments and developments. This, in turn, is reshaping the way we currently operate the supply chain and underscores the necessity of transitioning toward the digitalization of the pharmaceutical supply chain.

### Decentralized clinical trials

Decentralized clinical trials (DCTs) represent a paradigm shift in the way clinical research is conducted.

Unlike traditional clinical trials that typically require patients to visit centralized study sites, DCTs leverage digital technologies to enable participants to contribute data from their own homes or local healthcare facilities. Implementing decentralized trials introduces considerations points that will affect the Supply Chain Operations as they are now. One clear example will be the distribution of study materials (such as investigational drugs, medical devices, and bio samples) to participants' homes or local facilities requires. This process demands specific logistics, tracking mechanisms and a robust digital infrastructure, including secure data collection platforms, remote monitoring tools, and electronic informed consent systems (to ensure as well data security, quality and standardization).

### Cell & Gene Therapy

Cell and gene therapies are at the forefront of personalized medicine. They have emerged as transformative fields in medicine, holding great promise for treating a wide range of diseases. Some of the characteristics related to Cell & Gene Therapy (and individualized medicine), however, make their Supply Chain notably intricate due to several factors, such as Patient-Centric Approach, Cold Chain Logistics, Data Privacy and Security, Data Integration and Sharing.<sup>5</sup>

### Radioactive Medicine at Nano Level

The integration of nanotechnology with radioactive isotopes for diagnostic and therapeutic applications has the potential to revolutionize medical imaging, targeted therapy, and disease management. However, it also presents unique logistics challenges, that need to be addressed for successful development and deployment, for example Safe Handling, Quality Assurance, Storage and Transport, Stability and Shelf Life.

<sup>5</sup> Pharma.Aero Cell and Gene Therapies - Focus on Logistical Challenges, 2023.



## Digital Solutions for Evolving Trends and Challenges

### Achieving End-to-End visibility in Cold Chain with Internet of Things (IoT) and Sensors

Internet of Things (IoT) and sensor technology have emerged as powerful digital, addressing critical challenges such as cold chain management, supply chain transparency, visibility, and track-and-trace systems. They enable real-time monitoring, data collection, and analysis, thus revolutionizing the way pharmaceutical products are handled, transported, and tracked throughout the supply chain.

In the context of pharmaceutical logistics, IoT-enabled sensors can be embedded in various points along the supply chain, from manufacturing facilities to distribution centres and ultimately to end-user destinations, to enable the end-to-end monitoring of the conditions, location, and integrity of pharmaceutical products. In case of deviations, IoT sensors can trigger alerts, allowing swift intervention to rectify any issues and prevent potential losses.

By gathering data-driven insights, such as excessive dwell times or inefficient routes, pharmaceutical companies can streamline the logistics operations, to reduce operational costs and minimize the carbon footprint associated with transportation.

Also, the data collected by sensors can serve as valuable documentation for compliance audits, quality control checks, and regulatory reporting.

IoT systems generate copious amounts of data encompassing temperature logs, environmental conditions, and geographical coordinates. This data is collected, stored, and analysed to unravel patterns and trends, steering process enhancements and informed decision-making, while offering support for compliance assessments and investigative efforts.

Ultimately, Risk Mitigation emerges as a substantial advantage. IoT's integration into Cold Chain Management substantially curbs the risks associated with temperature excursions.





## Enabling Predictive Risk Mitigation with Artificial Intelligence (AI)

In recent years, the integration of Artificial Intelligence (AI) and Machine Learning (ML) technologies within the pharmaceutical logistics sector has emerged as a significant trend to address the challenges associated with the intricate and sensitive nature of pharmaceutical supply chains.

One example is predictive risk mitigation, where AI and ML work in tandem to analyse vast amounts of data and extract valuable insights. AI systems pre-process the data to ensure its quality and suitability for analysis. AI and ML models are "trained" on historical data to learn patterns, and correlations. Various ML algorithms are used, such as decision trees, neural networks, or support vector machines, depending on the complexity of the problem. Finally, the trained model is fine-tuned to optimize its predictive accuracy. This involves adjusting parameters and optimizing hyperparameters. As new data streams in, the AI system applies the trained model to predict outcomes. When the AI system detects a potential risk, it generates alerts or notifications for stakeholders, enabling them to take proactive actions. This is the end goal of applying AI and ML in pharma logistics.

Route optimization and delay prediction is also benefiting from new technologies supported by AI and ML. AI process real-time traffic data, weather conditions, and all historical route performance, to predict potential delays or disruptions, and suggests alternative routes or re-routing strategies to ensure on-time deliveries.

## Provide Transparency and Security with Blockchain Technology

The emergence of blockchain technology offers a revolutionary solution for enhanced visibility, accountability, and security.

Blockchain is a decentralized and distributed digital ledger technology that records and verifies transactions across multiple computers. Each transaction, or block, is linked to the previous one, creating a chain of blocks. This structure ensures that once a record is added, it cannot be altered, making it highly secure and transparent. In the context of pharmaceutical logistics, blockchain enables the creation of an unbroken and verifiable chain of custody for products, from raw materials to the end consumer. Every interaction, including manufacturing, transportation, and storage, is recorded and can be audited at any time.

By leveraging these characteristics, pharmaceutical companies aim to achieve an end-to-end traceability system that guarantees product authenticity, minimizes counterfeits, and ensures timely delivery to patients.

Blockchain assists in meeting regulatory requirements by providing a verifiable record of each product's journey. This aids in adhering to industry standards and regulations.

Smart contracts, self-executing agreements with predefined conditions, would be used to automate various processes, such as quality control checks, regulatory compliance, and payments, thus reducing the need for intermediaries and streamlining operations.



Blockchain's transparent and immutable characteristics are well-suited for tackling challenges like counterfeit drugs, supply chain inefficiencies, product integrity assurance, regulatory compliance, and ensuring patient safety.

“Blockchain can allow to automatically trigger payments, instead of the now typical 90 days payment condition. The stakeholders can be paid as soon as their job is done.”

~ Hive-Zox

## Combined Digital Solutions for Sustainability Improvement

The integration of digital solutions into pharma logistics aligns with the broader global drive towards sustainability. By enhancing visibility, traceability, and control throughout the supply chain, the stakeholders simultaneously reduce the carbon footprint and waste associated with traditional logistics approaches.

The concept underlying this trend is the comprehensive digitalization of the pharmaceutical supply chain, by integrating various technologies such as the Internet of Things (IoT), blockchain, data analytics, and artificial intelligence (AI). These technologies work in synergy to create a transparent, efficient, and sustainable logistics ecosystem.

For route optimization, AI can be a game-changer in logistics sustainability. Advanced algorithms consider real-time traffic conditions, weather forecasts, delivery windows, and fuel efficiency of vehicles. By optimizing routes, companies can minimize fuel consumption, lower emissions, and reduce transportation costs. This not only benefits the environment by reducing the carbon footprint of transportation operations but also contributes to cost savings for businesses.

“Carbon assessment is finding its way as part of lane risk assessment.”

~ SmartCAE



## Case Study: MSD – Applicability of Next-Gen Digital Technologies

MSD (Merck Sharp & Dohme) is a global pharmaceutical company that is embracing digital logistics to transform its supply chain operations. By leveraging advanced technologies and data analytics, MSD aims to enhance visibility, traceability, security, and condition monitoring throughout its supply chain. This chapter presents MSD's implementation of a cloud-based shipment visibility tool and the positive outcomes and achievements it has witnessed.

MSD is a leading pharmaceutical company with a global footprint. Its primary goal is to improve human health by delivering innovative medicines, vaccines, and animal health products. Operating in multiple sectors, including preventive and therapeutic medicine, MSD has a vast network of factories, distribution centres, and partners involved in the international transportation of its products. Ruud van der Geer and Jana Zurfluh explain how MSD is involving Next-Gen Digital Technologies in their logistics:

MSD implemented a cloud-based shipment visibility tool as part of its digital logistics program. This tool allows for real-time tracking, security monitoring, reliability assessments, quality control, and lane optimization. The solution connects various nodes in the supply chain and enables the exchange of information, leading to enhanced visibility and streamlined operations.

The main goals of MSD's digital logistics program were:



Receive  
Real-time  
alerts



Implement  
interventions  
when  
necessary



Provide  
accurate  
customer  
ETA advice



Improve  
performance  
management



Conduct risk  
analyses and  
drive business  
improvement



Enable  
strategic  
planning

The first three goals have been achieved, with the company successfully implementing real-time alerts, interventions, and accurate customer ETA advice. The remaining goals, such as performance management and risk analysis, are currently a work in progress and will continue to be developed. Overall, MSD's digital logistics program has already delivered significant value to the company and its customers. Prior to implementing the digital logistics solutions, MSD faced several challenges. These included the need for a strong business case to secure funding, meeting tight development timelines, and choosing suitable off-the-shelf application that required further customization.




The challenges were mitigated successfully as the Proof of Concept (POC) delivered a quick and positive Return on Investment (ROI). The solution proved its effectiveness and provided tangible benefits, alleviating concerns and uncertainties surrounding the implementation.

During the implementation phase, MSD encountered challenges such as obtaining collaboration from different sites, stepping outside existing Standard Operating Procedures (SOPs), and transitioning from the POC to the industrialization phase. Overcoming these challenges required close collaboration, effective change management, and clear communication across the organization.

To successfully launch the initiative, MSD had to ensure good quality master data, adherence to procedures, and a focus on starting small to limit scope and manage risks. The availability of reliable master data and adherence to procedures played a crucial role in setting a solid foundation for the implementation.

The main learning from MSD's digital logistics program was the importance of having a clear strategy and aligning it with a strong business case. Starting with immediate impact and value for the business provided a foundation on which to expand and achieve broader strategic goals.

**Teamwork, focus, and dedication were key elements in the successful implementation. The program witnessed several positive outcomes and highlights:**



Since the launch of the industrialized program, over 6,400 shipments containing more than 300 million doses have been tracked.

### Case Study

During a shipment of a product from Europe to Asia, an alert was generated by the cloud-based shipment visibility tool, due to the increasing temperature of the shipment. Upon evaluation, it was discovered that the worn shipping container had been used. The shipment was swiftly returned to origin, and over 3,000 doses of this high value product were saved through this intervention. This example highlights the effectiveness of real-time monitoring and intervention capabilities offered by MSD's digital logistics solution.

MSD's digital logistics program is revolutionizing the pharma supply chain by leveraging advanced technologies (such as IoT and data analytics). The implementation of a cloud-based shipment visibility tool has significantly enhanced visibility, traceability, security, and condition monitoring. Through collaborative efforts, the company has overcome challenges, achieved its initial goals, and witness positive outcomes. This transformation in logistics sets MSD apart in the industry, ensuring efficient delivery of critical pharmaceutical products worldwide.






## Implementation Challenges and Enablers for Digital Solutions

Implementing digital technologies is not without its complexities as there are many roadblocks to realizing the full potential of digitalization in pharma logistics and transportation.

### Infrastructure and Integration

Infrastructure and integration play a pivotal role in the successful implementation of digital solutions within the pharmaceutical logistics and transportation sector. A robust and adaptable infrastructure is essential to support the deployment of new technologies. It involves both hardware and software components, along with the networking infrastructure.

One of the key enablers is assessing current infrastructure's capabilities and limitations, as explained in:



“ To integrate, the backbone should be solid, one ERP, one TMS company wide. Integration is a lot easier.”

~ MSD



## Data Security and Privacy

Securing sensitive data, protecting against cyber threats, and ensuring compliance with data privacy regulations are critical considerations when implementing technology solutions. Even more in the healthcare sector, ensuring the confidentiality, integrity, and availability of data is essential for maintaining trust, securing access to healthcare and saving lives.

To accelerate data security and privacy efforts, invest in state-of-the-art encryption tools, access management systems, and data security software. Regular security audits and vulnerability assessments can help identify and address potential weaknesses. The adoption of security AI and automation is crucial for cost reduction and faster breach identification and containment.

## Regulatory Compliance

Technology applications must align with regulatory guidelines and compliance requirements.

The key enabler here is a proactive approach to regulatory compliance. Organizations must stay informed about the latest regulations and standards that apply to their operations and how implementing new technologies could impact those regulations.

## Training and Workforce Skills

The successful implementation of digital solutions relies heavily on the skills and adaptability of the workforce. Resistance to change and a lack of digital literacy can hinder the adoption of new technologies.

Investing in training programs to upskill your workforce is the primary enabler in this context.

To accelerate the adoption of digital solutions, develop comprehensive training programs tailored to different user groups within your organization.

Encourage a culture of continuous learning and provide resources for employees to enhance their digital skills.

Resistance to change is a prevalent challenge when implementing digital solutions in any organization. This resistance can manifest as a reluctance among employees to embrace new technologies, which, in turn, can lead to slow adoption rates. To ensure the successful integration of digital solutions, it's essential to address this common pitfall effectively, with change management strategies, leadership support and effective communication.

“ For a data community, Change management is a challenge, to get all stakeholders on the platform.”

~ KatalX



## Rapid Innovations

The pharmaceutical logistics industry is witnessing rapid technological advancements. Embracing innovation and staying ahead is essential for maintaining competitiveness.

The enabler here is a proactive approach to innovation. Organizations must foster a culture of continuous innovation and adaptability. This involves staying informed about emerging technologies and trends.

## Precision & Personalized Medicine

In the domain of patient treatments, the transition from a "one-to-many" approach to a more personalized "one-to-one" offering, often referred to as "precision medicine," has the potential to significantly impact the functioning of supply chains

The adoption of more precise medicine inevitably places greater demands on the logistics involved, necessitating robust scheduling and sophisticated coordination capabilities. This heightened level of precision introduces complexities into supply chains, including the management of specialized chains such as cold chains and cryo-chains.

**In the future, supply chains may need to adapt to accommodate "at-home" models, such as transitions from B2B to B2B2C and B2C. In these models, the last mile of delivery becomes critically important, necessitating effective management of controls and transparency requirements.**

However, it's important to acknowledge that significant work remains to be done to realize this future vision. Operational complexity arises from the challenge of tracking an individual's genetic material or proteins, and different supply chain pathways will be necessary depending on the specific treatment required.





## Exploring Emerging Trends And Transformations

# Sectoral Changes Impacting Life Sciences and Pharma in the Next Years

### MedTech

MedTech (medical technology) supply chains are inherently complex due to the multitude of components involved in the final product. These components are sourced from various supply chains and partners, demanding meticulous inventory management and delivery oversight, along with careful device maintenance.

As the landscape evolves, new business models within the MedTech industry are likely to emerge. These models may encompass direct-to-consumer and as-a-service approaches, along with services integrated with products.

### Data-as-a-Service (DaaS)

Data holds an ever-increasing significance for healthcare and life sciences organizations. Organizations have the opportunity to view DaaS as a means to monetize their data and gain a competitive edge.


Furthermore, leveraging DaaS has the potential to streamline and integrate various activities within an organization, thereby enhancing productivity, improving efficiencies, and ultimately reducing costs and lead times. In essence, DaaS empowers healthcare and life sciences organizations to harness the full potential of data while addressing privacy and storage considerations.

### Metaverse

The metaverse, a digital universe of interconnected virtual environments, is a concept rapidly gaining traction across various industries.

For the field of pharma supply chain and logistics, the metaverse development promises profound benefits for planning teams, offering advanced features like enhanced demand forecasting, hyper-precise modelling, and collaborative scenario-planning with suppliers and customers.

In the medical sphere, metaverse tools enable the consolidation of personal data from diverse sources, such as smartphones, wearable devices, blood tests, and DNA analyses, to construct a comprehensive patient profile. This data serves as the foundation for modelling various treatment scenarios based on health data, ultimately leading to highly personalized treatments.





## Converging Technologies: Self-driving Supply Chain

The evolution of various cutting-edge technologies, such as the Internet of Things (IoT), Artificial Intelligence (AI), Blockchain, and more, promises to converge into a unified platform that can act as a control tower, a cognitive command center, for logistics and supply chain management. This visionary concept entails a seamless integration of these technologies to lead in the era of self-planning logistics and supply chains.

IoT sensors and devices will continue to grow across the supply chain, providing real-time visibility into every aspect of logistics operations. From tracking the location and condition of goods to monitoring equipment performance, IoT data will form the foundation of an interconnected supply chain ecosystem.

AI algorithms should evolve to process vast volumes of IoT-generated data. These advanced AI systems will not only provide insights but also make autonomous decisions in real time. Predictive analytics and machine learning models will optimize routes, inventory levels, and demand forecasting with unprecedented accuracy.

Blockchain technology will play a pivotal role in ensuring trust and transparency within the supply chain. It will facilitate secure and immutable data sharing among stakeholders, reducing fraud and errors.

With the current trending next-gen technologies, the future of logistics and supply chain management is set up for a remarkable transformation as various technologies converge into a unified platform. This cognitive command centre will enable self-planning logistics and supply chains, optimizing operations with unprecedented precision and adaptability. With data-driven decision-making, trust facilitated by blockchain, and the power of AI, the supply chain of the future will be not just efficient but also transparent, ethical, and highly resilient.

“ Digitization is key. Ability to digitize factory, shipment, and consolidate that data in one portal. There are different systems for different things. Coordination into 1 system is critical.”

~ ColdChase



## Conclusions

The pharmaceutical supply chain is one of the most complex and regulated, with unique challenges that need to be addressed, to ensure people's access to healthcare. The digital technologies play a fundamental role, and the digital transformation is a necessity. The adoption of digital technologies offers a clear path to enhancing supply chain efficiency, resilience, and adaptability. Those who have not yet embraced this transformation or are in the early stages must act decisively.

### **Start Small for Quick Wins:**

Begin by identifying areas where digital technology can be quickly integrated to improve collaboration, responsiveness, and agility. These early successes can serve as building blocks for broader transformation efforts.

### **Data-Driven Decision-Making:**

Collect and analyse downstream demand data to enhance forecasting and planning, helping your company make informed, data-driven decisions.

### **Patient-Centric Transformation:**

Shift your operating model from being supply-driven to patient-driven, aligning your strategies with the needs and expectations of your patients.

### **Embrace innovative business models:**

It is not just about adopting new technology, but also reimagining new business models, to benefit from the advantages they can offer.

### **Workforce Transformation:**

Understand that successful digital implementation relies on a skilled and adaptable workforce. Develop comprehensive training programs tailored to different user groups to overcome resistance to change and improve digital literacy.

### **Infrastructure Investment:**

A robust and adaptable infrastructure is essential for the successful deployment of digital solutions. Assess your existing infrastructure and invest in the necessary upgrades to support your digitalization strategy effectively.

In this rapidly changing landscape, companies that embrace digital transformation can gain a competitive edge, improve operational efficiency, and respond more effectively to future disruptions and ways of working. It's not merely an investment in technology but an investment in the future of pharmaceutical logistics. The time to act is now, as the digital leaders of today will be better positioned to meet the demands of tomorrow.



## Acknowledgements

We would like to sincerely thank the project leads for their time and guidance: Irene S L Lau, Caroline Y W Cheung, Sharon S K Yip (Hong Kong Airport), Yue Ming, Liew Zhong Yao, Renee Gan (Changi Airport). Thank you to Samuel Speltdoorn (Brussels Airport), Board Liaison.

Thank you to the project members for being part of the interviews and bringing valuable content to the table: Alexandre Bosdonnat (LAINPHARMA), Charles Bourbonnais (Hive-Zox), Damien de Chillaz (KatalX), Eelco de Jong (Validaide), Francesco Di Martino (Pharma Air Logistics Group), Rosy Amlani (Cold Chase), Stefan Braun (SmartCAE) and Yvonne Ziegler (Mytigate).

Special thanks to Virginia Domina, Righart Stroobant and Anne Julie Verhaeghe (KPMG Advisory BV/SRL), for managing and running the project, together with the coordination of Frank Van Gelder and Sara Van Lerberghe.

